John Seeger

Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.

Hoffman V, Hallas J, Linder M, Margulis AV, Suehs BT, Arana A, Phiri K, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Xu Y, Kristiansen NS, Appenteng K, de Vogel S, Seeger JD.

Drug Saf. 2021 Aug. 44(8):899-915. PMID: 34236595

A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder.

Phiri K, Hallas J, Linder M, Margulis A, Suehs B, Arana A, Bahmanyar S, Hoffman V, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Kristiansen NS, Appenteng K, de Vogel S, Seeger J.

Curr Med Res Opin. 2021 May. 37(5):867-877. PMID: 33591859

Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database.

Ziyadeh NJ, Geldhof A, Noël W, Otero-Lobato M, Esslinger S, Chakravarty SD, Wang Y, Seeger JD.

Clin Drug Investig. 2020 Nov. 40(11):1021-1040. PMID: 32779120

Methods for external control groups for single arm trials or long-term uncontrolled extensions to randomized clinical trials.

Seeger JD, Davis KJ, Iannacone MR, Zhou W, Dreyer N, Winterstein AG, Santanello N, Gertz B, Berlin JA.

Pharmacoepidemiol Drug Saf. 2020 11. 29(11):1382-1392. PMID: 32964514

Using RWE research to extend clinical trials in diabetes: An example with implications for the future.

Seeger JD, Nunes A, Loughlin AM.

Diabetes Obes Metab. 2020 04. 22 Suppl 3:35-44. PMID: 32250529

Risk of cardiovascular and cerebrovascular events and mortality in patients with migraine receiving prophylactic treatments: An observational cohort study.

Hoffman V, Xue F, Ezzy SM, Yusuf A, Green E, Eisele O, Kurth T, Seeger JD.

Cephalalgia. 2019 Oct. 39(12):1544-1559. PMID: 31195804

Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data.

Bykov K, He M, Franklin JM, Garry EM, Seeger JD, Patorno E.

Diabetes Obes Metab. 2019 09. 21(9):2029-2038. PMID: 31062453

Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population.

Funch D, Mortimer K, Ziyadeh NJ, Seeger JD, Li L, Norman H, Major-Pedersen A, Bosch-Traberg H, Gydesen H, Dore DD.

Diabetes Obes Metab. 2019 08. 21(8):1837-1848. PMID: 30945402

U.S. prevalence of endocrine therapy-naïve locally advanced or metastatic breast cancer.

Nunes AP, Liang C, Gradishar WJ, Dalvi T, Lewis J, Jones N, Green E, Doherty M, Seeger JD.

Curr Oncol. 2019 04. 26(2):e180-e187. PMID: 31043825

Effectiveness and Tolerability of Therapy With Once-Weekly Exenatide Versus Basal Insulin Among Injectable-Naive Patients With Type 2 Diabetes in a Real-World Setting in the United States.

Loughlin AM, Qiao Q, Nunes AP, Ezzy SM, Yochum L, Clifford CR, Gately RV, Dore DD, Seeger JD.

Diabetes Spectr. 2018 May. 31(2):129-137. PMID: 29773932